The Division of Drug Information (DDI)- serving the public by providing information on human drug products and drug product regulation by FDA.
FDA continues to work with CDC to find the source or sources of the Burkholderia cepacia outbreak and will provide additional information when it is available. At this time, there is no epidemiologic or laboratory evidence to suggest oral capsules or enemas are affected. Most importantly, we join CDC in recommending that facilities not use any oral liquid docusate products for patients who are critically ill, ventilated, or immunosuppressed. Additionally, facilities that experience B. cepacia complex infections among non-cystic fibrosis patients or clusters of B. cepacia complex infections among cystic fibrosis patients should sequester all oral liquid docusate products.
For more information, please visit: Burkholderia cepacia Infections.